OBJECTIVE: To determine the role of thyroid transcription factor-1 (TTF-1) as a prognostic factor in advanced adenocarcinoma of non-small cell lung cancer. MATERIAL AND METHOD: Retrospective cohort study among lung cancer patients with inoperable or metastases, adenocarcinoma type whose tumors were already tested for TTF-1 in Rajavithi Hospital from December 2003 to November 2011. The correlation of TTF-1 to survival period and the treatment outcomes were defined. RESULTS: Of 67 patients, 48 TTF-1 positive cases and 19 TTF-1 negative cases were included in the analysis. Median overall survival for all population was 263 days (111-415 days). No significant difference was found between TTF-1 positive and negative tumors (251 and 369 days, p-value = 0.8). The systemic treatment with chemotherapy was the only effective prognostic factor for survival of this study. CONCLUSION: The prognostic factor of TTF-1 positive and negative in advanced adenocarcinoma subtype of NSCLC was not different in median overall survival.
OBJECTIVE: To determine the role of thyroid transcription factor-1 (TTF-1) as a prognostic factor in advanced adenocarcinoma of non-small cell lung cancer. MATERIAL AND METHOD: Retrospective cohort study among lung cancerpatients with inoperable or metastases, adenocarcinoma type whose tumors were already tested for TTF-1 in Rajavithi Hospital from December 2003 to November 2011. The correlation of TTF-1 to survival period and the treatment outcomes were defined. RESULTS: Of 67 patients, 48 TTF-1 positive cases and 19 TTF-1 negative cases were included in the analysis. Median overall survival for all population was 263 days (111-415 days). No significant difference was found between TTF-1 positive and negative tumors (251 and 369 days, p-value = 0.8). The systemic treatment with chemotherapy was the only effective prognostic factor for survival of this study. CONCLUSION: The prognostic factor of TTF-1 positive and negative in advanced adenocarcinoma subtype of NSCLC was not different in median overall survival.